Valbiotis Raises €1.65 M in Bank Loans Without Dilution to Support Its Pharmacy Sales
The La Rochelle-based laboratory specializing in cardiometabolic health is using amortizing loans and receivables financing to support the ramp-up of its sales, particularly in pharmacies. Announced in a press release published on November 16, 2026, these resources are in addition to its existing cash, with no dilution for shareholders.
Three Fixed-Rate Loans, Including One with a Deferred Repayment at Bpifrance
Valbiotis has obtained three fixed-rate loans, for a total of €1.65 M. Its two historical banks, Société Générale and BNP Paribas, each granted it €600 k over a term of four years.
The third loan, of €450 k, comes from Bpifrance. Its total term reaches eight years, with a three-year repayment deferral followed by a five-year amortization period.
Sébastien Peltier, Chairman of the Management Board, sees in this the illustration of “our ability to obtain financing suited to each stage of our development.” According to him, these resources give the company “the means to support, under the best conditions, the ramp-up of our sales, particularly in pharmacies.”
A €500 k Factoring Arrangement Linked to Payment Terms in Pharmacies
In parallel, Valbiotis has signed a factoring agreement with BNP Paribas Factor, with an authorized financing facility of €500 k. This ceiling may be increased at any time during the term of the contract, depending on business growth.
This arrangement is intended to finance the working capital requirement linked to trade receivables. According to the company, this requirement should increase with the expected rise in revenue in pharmacies, a channel where payment terms are 45 days end of month.
These financings supplement the €11.7 M in cash held as of June 30, 2026, which provide Valbiotis with a financing horizon through the end of 2027, excluding any additional source of financing. The company indicates that it can thus give priority to allocating its resources to the commercial rollout of its products.